Tulisokibart is a new investigational medication being studied for treating people with Crohn’s Disease and Ulcerative Colitis, which are inflammatory conditions affecting the digestive system. This medication is designed to help reduce inflammation in the intestines and manage the symptoms of these conditions over a long period of time. The medication is being tested to understand how safe it is and how well it works when used for extended treatment periods.

Crohn’s Disease – A chronic inflammatory condition that can affect any part of the digestive tract, from mouth to anus, but most commonly impacts the small intestine and colon. The inflammation can spread deep into the layers of affected bowel tissue, causing pain, severe diarrhea, and digestive problems. The disease typically develops in patches, with healthy sections in between affected areas. Symptoms can vary from mild to severe and may come and go with periods of active illness followed by remission.

Ulcerative Colitis – A chronic inflammatory bowel disease that causes inflammation and sores (ulcers) in the innermost lining of the large intestine (colon) and rectum. Unlike Crohn’s disease, this condition affects only the colon and rectum, with inflammation occurring in a continuous pattern. The disease usually begins in the rectum and spreads upward through the colon. Symptoms typically develop gradually over time rather than suddenly, with periods of active disease alternating with periods of remission.